Mielóma multiplex: vizsgálatok itt: Ausztria
15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
- Where
- Linz, Vienna
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06189833 · EU 2023-505221-14-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Innsbruck, Linz, St. Poelten, Vienna, Wels
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Linz, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Krems, Leoben, Sankt Pölten, Vienna
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Linz, Vienna
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Graz, Innsbruck, Linz, Rankweil, Salzburg, Sankt Pölten, Vienna, Wels
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Linz, St. Poelten, Vienna
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Innsbruck, Krems An Der Donau, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 3. fázisTaking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Linz, Salzburg, Vienna, Wiener Neustadt
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - 3. fázisTaking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Linz, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - No phaseTaking peopleEuropean Myeloma Network (EMN) Sample Project
- Where
- Linz, Vienna
- Életkor
- 18 év and over
- People
- 6000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06237803 - 3. fázisTaking peopleA randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
- Where
- Krems An Der Donau, Linz, Salzburg, St. Poelten, Vienna, Wels
- Életkor
- 18 év and over
- People
- 451 worldwide
- Run by
- Universitaetsklinikum Heidelberg AöR
See details and how to join2023-507402-13-00 · EU 2023-507402-13-00 - No phaseTaking peopleDeveloping a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
- Where
- Graz, Innsbruck, Kufstein
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Medical University Innsbruck
See details and how to joinNCT06821880 - 2. fázisTaking peopleRSV Vaccination in Immunocompromised Patients.
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 200
- Run by
- Medical University of Vienna
See details and how to joinNCT06597916 - 2. fázisTaking peopleDaratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure
- Where
- Innsbruck
- Életkor
- 18 év and over
- People
- 50
- Run by
- Medizinische Universitaet Innsbruck
See details and how to join2024-514702-31-00 · EU 2024-514702-31-00